Literature DB >> 25704629

Epstein-Barr virus-positive diffuse large B-cell lymphoma in children: a disease reminiscent of Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly.

Stefania Uccini1, Mazin F Al-Jadiry2, Stefania Scarpino3, Daniela Ferraro3, Adel R Alsaadawi4, Amir F Al-Darraji5, Maria Luisa Moleti6, Anna Maria Testi6, Salma A Al-Hadad2, Luigi Ruco3.   

Abstract

Pediatric Epstein-Barr virus (EBV)-positive diffuse large B-cell lymphoma (EBV+ DLBCL) is a rare disease in nonimmunocompromised hosts. In a review of 231 cases of malignant lymphoma (87 Hodgkin lymphoma and 144 non-Hodgkin lymphoma) occurring in Iraqi children, 7 cases (5% of NHLs) were classified as EBV+ DLBCL. Six children presented with nodal disease, and 1 presented with extranodal localization (bone). In all cases, the disease was at an advanced clinical stage (III/IV). Evidence of immunodeficiency (Evans syndrome and selective IgA deficiency) was observed in a single case. Two cases were "monomorphic" with immunoblastic histology, and 5 cases were "polymorphic" with histologic aspects reminiscent of nodular lymphocyte-predominant Hodgkin lymphoma (2 cases) and of CD30+ classical Hodgkin lymphoma (3 cases). In all cases, tumor cells were EBV infected (EBER+/LMP-1+), were medium-large B-cells (CD20+/CD79a+/PAX-5+/BOB-1+/OCT-2+) of non-germinal center (non-GC) origin (CD10-/MUM-1+), and had high proliferative activity (50%-70%). Chromosomal translocations involving BCL2, MYC, and IGH genes were not observed. IGH monoclonality could be demonstrated in 3 of 3 investigated cases. Six cases of EBV-negative DLBCL (4% of NHL) were present in the same series. All had monomorphic histology with centroblastic/immunoblastic morphology; 3 cases were of GC type and 3 of non-GC type. Our findings indicate that in Iraq, DLBCLs are 9% of NHLs. Moreover, 2 different types of the disease do exist; the EBV-positive cases, with strong histologic and immunohistochemical resemblance with EBV+ DLBCL of the elderly, and the EBV-negative cases, which are similar to the pediatric DLBCL usually observed in Western populations.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Asia; Children; Diffuse large B-cell lymphoma (DLBCL); Epstein-Barr virus (EBV); Pathology

Mesh:

Year:  2015        PMID: 25704629     DOI: 10.1016/j.humpath.2015.01.011

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  12 in total

1.  EBV-positive large B-cell lymphomas in young patients: a nodal lymphoma with evidence for a tolerogenic immune environment.

Authors:  Alina Nicolae; Stefania Pittaluga; Shahed Abdullah; Seth M Steinberg; Thu Anh Pham; Theresa Davies-Hill; Liqiang Xi; Mark Raffeld; Elaine S Jaffe
Journal:  Blood       Date:  2015-05-21       Impact factor: 22.113

Review 2.  Cancers associated with human gammaherpesviruses.

Authors:  Kwun Wah Wen; Linlin Wang; Joshua R Menke; Blossom Damania
Journal:  FEBS J       Date:  2021-09-18       Impact factor: 5.622

3.  Cutaneous Involvement in Diseases with Plasma Cell Differentiation: Diagnostic Approach.

Authors:  Magda Zanelli; Andrea Palicelli; Francesca Sanguedolce; Maurizio Zizzo; Alessandra Filosa; Linda Ricci; Camilla Cresta; Giovanni Martino; Alessandra Bisagni; Eleonora Zanetti; Francesco di Donato; Beatrice Melli; Alessandra Soriano; Luca Cimino; Alberto Cavazza; Lisa Francesca Vivian; Stefano Ascani
Journal:  Curr Oncol       Date:  2022-04-24       Impact factor: 3.109

4.  CD5 positivity is an independent adverse prognostic factor in elderly patients with diffuse large B cell lymphoma.

Authors:  Wen-Yu Chuang; Hung Chang; Lee-Yung Shih; Po-Nan Wang; Yu-Sun Chang; Tung-Liang Lin; Yu-Shin Hung; Chi-Ju Yeh; Shir-Hwa Ueng; Tzung-Chih Tang; Ming-Chung Kuo; Po Dunn; Jin-Hou Wu; Hsiao-Wen Kao; Che-Wei Ou; Yung-Liang Wan; Chuen Hsueh
Journal:  Virchows Arch       Date:  2015-09-14       Impact factor: 4.064

5.  Intrafollicular Epstein-Barr virus-positive large B cell lymphoma. A variant of "germinotropic" lymphoproliferative disorder.

Authors:  Luisa Lorenzi; Silvia Lonardi; Murad H M Essatari; Vilma Pellegrini; Simona Fisogni; Anna Gazzola; Claudio Agostinelli; William Vermi; Giuseppe Rossi; Giovannino Massarelli; Stefano A Pileri; Fabio Facchetti
Journal:  Virchows Arch       Date:  2016-01-13       Impact factor: 4.064

Review 6.  Treatment Advances in EBV Related Lymphoproliferative Diseases.

Authors:  Kebing Lv; Ting Yin; Min Yu; Zhiwei Chen; Yulan Zhou; Fei Li
Journal:  Front Oncol       Date:  2022-04-19       Impact factor: 5.738

7.  Age cutoff for Epstein-Barr virus-positive diffuse large B-cell lymphoma--is it necessary?

Authors:  Chi Young Ok; Qing Ye; Ling Li; Ganiraju C Manyam; Lijuan Deng; Rashmi R Goswami; Xiaoxiao Wang; Santiago Montes-Moreno; Carlo Visco; Alexandar Tzankov; Karen Dybkaer; Li Zhang; Jeremy Abramson; Aliyah R Sohani; April Chiu; Attilio Orazi; Youli Zu; Govind Bhagat; Kristy L Richards; Eric D Hsi; William W L Choi; J Han van Krieken; Jooryung Huh; Maurilio Ponzoni; Andrés J M Ferreri; Shanxiang Zhang; Ben M Parsons; Mina Xu; Michael B Møller; Jane N Winter; Miguel A Piris; Zijun Y Xu-Monette; L Jeffrey Medeiros; Ken H Young
Journal:  Oncotarget       Date:  2015-06-10

Review 8.  EBV-Positive Lymphoproliferations of B- T- and NK-Cell Derivation in Non-Immunocompromised Hosts.

Authors:  Stefan D Dojcinov; Falko Fend; Leticia Quintanilla-Martinez
Journal:  Pathogens       Date:  2018-03-07

9.  Pediatric Pulmonary Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma: A Case Report and Review of the Literature.

Authors:  Eric X Wei; Roberto F Silva; James D Cotelingam; Rodney E Shackelford
Journal:  Case Rep Pathol       Date:  2017-10-08

10.  Cytotoxic response against Epstein Barr virus coexists with diffuse large B-cell lymphoma tolerogenic microenvironment: clinical features and survival impact.

Authors:  Melina Cohen; Aldana G Vistarop; Fuad Huaman; Marina Narbaitz; Fernanda Metrebian; Elena De Matteo; María V Preciado; Paola A Chabay
Journal:  Sci Rep       Date:  2017-09-07       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.